Onkos Surgical announced today that it agreed to acquire the Juvenile Tumour System (JTS) from Stryker (NYSE:SYK).
Parsippany, New Jersey–based Onkos entered into a definitive agreement with the orthopedic technology giant over the system designed to enable limb stabilization and growth in pediatric patients affected by bone cancers, severe arthropathy, severe trauma, revisions, oncology and malignant diseases.
The financial terms of the deal were not disclosed.
Onkos, which specializes in solutions for musculoskeletal oncology and other complex orthopedic conditions, said in a news release that the JTS allows for the non-invasive lengthening of the implant post-surgery over time in a clinical setting.
The design of JTS eliminates the need for multiple lengthening surgeries, anesthesia or sedation, therefore helping to reduce the risk of complications and cost associated with limb reconstruction surgery.
“This is a significant day for Onkos Surgical and the musculoskeletal oncology community,” Onkos co-founder and CEO Patrick Treacy said in the release. “Our ‘why’ has always driven us to specifically address the many clinical challenges this community of surgeons and patients face on a daily basis. Pediatric cancer surgery and limb lengthening are complex and challenging procedures, and the JTS extendible prosthesis is a solution in service of this mission.
“We are committed to being good stewards of the technology. We are proud to collaborate with this dedicated surgeon community and excited to create a bright future for the technology as we continue this meaningful work for pediatric musculoskeletal cancer patients.”
